Regulus Therapeutics Company Profile (NASDAQ:RGLS)

Regulus Therapeutics trades on the NASDAQ under the ticker symbol "RGLS."

Regulus Therapeutics Inc. (NASDAQ:RGLS) posted its quarterly earnings results on Tuesday, August, 1st. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.31) by $0.10. The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.02 million. Regulus Therapeutics had a negative return on equity of 173.20% and a negative net margin of 31,460.47%. View Regulus Therapeutics' Earnings History.

Regulus Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, November, 7th 2017. View Earnings Estimates for Regulus Therapeutics.

6 brokerages have issued 12-month price objectives for Regulus Therapeutics' stock. Their predictions range from $1.00 to $9.00. On average, they expect Regulus Therapeutics' share price to reach $4.10 in the next twelve months. View Analyst Ratings for Regulus Therapeutics.

Here are some recent quotes from research analysts about Regulus Therapeutics stock:

• 1. According to Zacks Investment Research, "Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs, called microRNA therapeutics. The Company's products aim to treat or prevent hepatitis C infections, cardiovascular disease, fibrosis, oncology, immuno-inflammatory diseases, and metabolic diseases. Regulus Therapeutics Inc. is based in La Jolla, California. " (9/19/2017)
• 2. Needham & Company LLC analysts commented, "Regulus provided a 2Q17 corporate update yesterday. RG-012 Phase 2 trial protocols have been submitted to FDA, sites have been selected, and enrollment is expected to begin soon. Mgmt reiterated guidance for biomarker data 4Q17 and interim clinical efficacy data mid-2018, followed by final results YE18. Mgmt also reiterated plans for an IND submission for RGLS4326, in development for Autosomal Dominant Polycystic Kidney Disease, by YE17. As a reminder, several programs were discontinued in Jun 2017. Company efforts are now directed primarily to the two lead programs, although a microRNA R&D effort remains underway." (8/2/2017)
• 3. Wedbush analysts commented, "RGLS reported Q4/FY16 revenues of $0.02MM/$1.2MM vs. consensus estimates of $0.2MM/$1.4MM and GAAP EPS (loss) of $(0.38)/$(1.55) vs. consensus estimates of $(0.34)/$(1.52). RGLS ended 2016 with cash and cash equivalents of $76.1MM, which we project to provide cash runway into mid:18 aligned with guidance... Following completion of the multiple ascending dose (MAD) study of RG-012 in healthy volunteers in Q2:17, RGLS is planning to initiate a Phase 1/2 renal biopsy study in AS patients that will evaluate RG-012 tissue PK, target engagement, and effects on disease biomarkers. We believe positive results in-line with RGLS' preclinical data could be indicative of future success." (3/6/2017)
• 4. Cowen and Company analysts commented, "Regulus reported Q4 earnings and provided a pipeline update." (3/3/2017)
• 5. Cantor Fitzgerald analysts commented, "We reiterate our Overweight rating on RGLS stock, but we are lowering our PT by $4 to $7, as a result of a reduction in our pTS estimate for the RG-101 program from 50% to 25%. We believe that "platform buyers" could still be attracted to the stock, but that investors seeking commercial proof of concept may have been put somewhat at bay given the delay in the FDA lift of the clinical trial hold for RG-101 as a treatment for infection with the HCV." (3/3/2017)

Regulus Therapeutics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 3,529,089 shares, an increase of 32.7% from the August 15th total of 2,660,204 shares. Based on an average daily trading volume, of 552,900 shares, the short-interest ratio is currently 6.4 days. Approximately 4.6% of the company's shares are sold short.

Some companies that are related to Regulus Therapeutics include Nabriva Therapeutics AG (NBRV), Horizon Discovery Group PLC (HZD), Curis (CRIS), Organovo Holdings (ONVO), Organovo Holdings (ONVO), Merrimack Pharmaceuticals (MACK), Compugen (CGEN), Advaxis (ADXS), Chromadex Corp (CDXC), OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), Oramed Pharmaceuticals (ORMP), GTx (GTXI), Silence Therapeutics plc (SLN) and Novelion Therapeutics (NVLN).

Regulus Therapeutics' management team includes the folowing people:

• Stelios B. Papadopoulos Ph.D., Chairman of the Board
• Joseph P. Hagan, President, Chief Executive Officer, Principal Executive Officer, Director
• Daniel Chevallard, Chief Financial Officer, Principal Financial and Accounting Officer
• Mark Deeg, Chief Medical Officer
• B. Lynne Parshall J.D., Director
• Douglas E. Williams Ph.D., Director
• David Baltimore Ph.D., Independent Director
• Mark G. Foletta CPA, Independent Director
• William H. Rastetter Ph.D., Independent Director

Regulus Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), EcoR1 Capital LLC (3.57%), Vanguard Group Inc. (2.76%), South Dakota Investment Council (2.50%), Wells Fargo & Company MN (1.31%) and Goldman Sachs Group Inc. (0.35%). Company insiders that own Regulus Therapeutics stock include Alnylam Pharmaceuticals, Inc, Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Institutional Ownership Trends for Regulus Therapeutics.

Regulus Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN and Vanguard Group Inc.. View Insider Buying and Selling for Regulus Therapeutics.

Regulus Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Goldman Sachs Group Inc., LMR Partners LLP, GSA Capital Partners LLP, Quantitative Investment Management LLC, FMR LLC, Royal Bank of Canada and Wedbush Securities Inc.. Company insiders that have bought Regulus Therapeutics stock in the last two years include Daniel R Chevallard, Joseph P Hagan, Stelios Papadopoulos and William H Rastetter. View Insider Buying and Selling for Regulus Therapeutics.

Shares of Regulus Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Regulus Therapeutics stock can currently be purchased for approximately $1.31.